Answers are grounded in this paper and cite their sources.
Explores sustainability in pharmaceutical R&D, highlighting clinical pharmacology's role in reducing carbon footprints.
With society's rising concern over resource expenditures, sustainable solutions are sought across industries. The pharmaceutical research & development (R&D) enterprise faces the dual challenge of navigating the complexity of human disease and a highly regulated environment, leading to extensive data generation to ensure patient-focused development of optimal therapeutics. Through innovative study designs, translational technologies, and model-informed approaches, clinical pharmacology as a discipline can meaningfully contribute to reducing drug development's carbon footprint and achieving sustainability goals.
No takes yet. Share an insight, caveat, or question.
Onufrak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: